CD8A and COVID-19: CyTOF has also been used to assess the efficacy of emerging forms of treatment for COVID-19, including mesenchymal stem cell transplantation, by precisely characterizing the different subsets of immune cells such as CXCR3+CD4+ T cells, CD8+ T cells, and NK cells.83